Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology
Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF(165)). In this conte...
Saved in:
| Published in | Clinical ophthalmology (Auckland, N.Z.) Vol. 1; no. 4; pp. 393 - 402 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Taylor & Francis Ltd
01.12.2007
Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF(165)). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF(165) and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects. |
|---|---|
| AbstractList | Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF(165)). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF(165) and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects. Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF165). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF165 and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects. Keyword: anti-VEGF aptamer, pegaptanib, age-related macular degeneration Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF 165 ). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF 165 and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects. |
| Author | Ulrich, Henning Martins, Antonio H Alves, Janaína M Trujillo, Cleber A Nery, Arthur A |
| AuthorAffiliation | 1 Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil 2 Departamento de Neurologia Experimental, Universidade Federal de São Paulo, São Paulo, Brazil |
| AuthorAffiliation_xml | – name: 1 Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil – name: 2 Departamento de Neurologia Experimental, Universidade Federal de São Paulo, São Paulo, Brazil |
| Author_xml | – sequence: 1 givenname: Cleber A surname: Trujillo fullname: Trujillo, Cleber A organization: Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil – sequence: 2 givenname: Arthur A surname: Nery fullname: Nery, Arthur A – sequence: 3 givenname: Janaína M surname: Alves fullname: Alves, Janaína M – sequence: 4 givenname: Antonio H surname: Martins fullname: Martins, Antonio H – sequence: 5 givenname: Henning surname: Ulrich fullname: Ulrich, Henning |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19668516$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkF9LwzAUxYNM3B_9ChLwwadCkzRN8yLI3KYw8EX3Wm7TdM1Im9qmg317O51DvS_3wvlxOOdO0ah2tb5AE0KECHiUsNH5jsUYTbtuF4YxDRNxhcZExnHCSTxBmye919Y1la49dgX2pcZQexNsFqslhsZDpVvsHYaj1EKje28Uhu2RL1yLlTW1UWCxa0pfgq2cddvDNboswHb65rRn6H25eJs_B-vX1cv8cR00lDIfqCLjUrMkV0pmSZFIJnnEqGAgYwpAIJI8zFUmCs6iJOehlsCIYoJkjAPhbIYevn2bPqt0roZULdi0aU0F7SF1YNK_Sm3KdOv2KRVhxCkbDO5PBq376HXn08p0SlsLtXZ9lwrGuBCcyIG8-0fuXN_WQ7uUfo2Qkg7U7e9A5yQ_H2efjb6AMQ |
| ContentType | Journal Article |
| Copyright | Copyright Taylor & Francis Ltd. 2007 2007 Dove Medical Press Limited. All rights reserved |
| Copyright_xml | – notice: Copyright Taylor & Francis Ltd. 2007 – notice: 2007 Dove Medical Press Limited. All rights reserved |
| DBID | NPM 3V. 7X7 7XB 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M2O MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DatabaseName | PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Research Library Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Research Library (Alumni Edition) Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1177-5483 |
| EndPage | 402 |
| ExternalDocumentID | 19668516 |
| Genre | Journal Article |
| GroupedDBID | --- 0YH 29B 2WC 53G 5VS 6J9 7X7 8AO 8FI 8FJ 8G5 ABDBF ABUWG ACGFO ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI C1A CCPQU DIK DWQXO E3Z EBD EBS EJD F5P FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IHW ITC KQ8 M2O M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RNS RPM TDBHL TR2 UKHRP VDV W2D 3V. 7XB 8FK K9. MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-p223t-cfb59e38dcc9b8f8939543273a962aa1a4950dcb7f5348d50e9a31c371b35a153 |
| IEDL.DBID | RPM |
| ISSN | 1177-5467 |
| IngestDate | Tue Sep 17 21:22:59 EDT 2024 Fri Aug 16 23:53:09 EDT 2024 Thu Oct 10 17:04:06 EDT 2024 Sat Sep 28 07:56:25 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | pegaptanib anti-VEGF aptamer age-related macular degeneration |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p223t-cfb59e38dcc9b8f8939543273a962aa1a4950dcb7f5348d50e9a31c371b35a153 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704523/ |
| PMID | 19668516 |
| PQID | 2222227992 |
| PQPubID | 3933183 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2704523 proquest_miscellaneous_733577519 proquest_journals_2222227992 pubmed_primary_19668516 |
| PublicationCentury | 2000 |
| PublicationDate | 20071201 |
| PublicationDateYYYYMMDD | 2007-12-01 |
| PublicationDate_xml | – month: 12 year: 2007 text: 20071201 day: 1 |
| PublicationDecade | 2000 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Auckland |
| PublicationTitle | Clinical ophthalmology (Auckland, N.Z.) |
| PublicationTitleAlternate | Clin Ophthalmol |
| PublicationYear | 2007 |
| Publisher | Taylor & Francis Ltd Dove Medical Press |
| Publisher_xml | – name: Taylor & Francis Ltd – name: Dove Medical Press |
| References | 9127985 - Harvey Lect. 1995-1996;91:47-57 8614266 - Life Sci. 1996;58(14):1149-57 7592749 - J Biol Chem. 1995 Oct 27;270(43):25702-8 10804084 - Oncologist. 2000;5 Suppl 1:3-10 11700390 - Oncologist. 2001;6 Suppl 5:32-9 15733988 - Am J Ophthalmol. 2005 Feb;139(2):271-9 16174643 - Hum Mol Genet. 2005 Nov 1;14(21):3227-36 7504300 - Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11227-31 13000707 - J Physiol. 1952 Oct;118(2):228-57 15350892 - Trends Mol Med. 2004 Sep;10(9):417-20 11279054 - J Biol Chem. 2001 May 11;276(19):16464-8 8248162 - Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10705-9 17306878 - Ophthalmology. 2007 May;114(5):847-54 9685413 - J Biol Chem. 1998 Aug 7;273(32):20556-67 10517237 - J Chromatogr B Biomed Sci Appl. 1999 Sep 10;732(1):203-12 11355345 - Biotechniques. 2001 May;30(5):1094-6, 1098, 1100 passim 15963620 - Biochimie. 2005 Sep-Oct;87(9-10):921-30 16940309 - Hum Mol Genet. 2006 Oct 1;15(19):2955-61 2200121 - Science. 1990 Aug 3;249(4968):505-10 7683111 - Nature. 1993 Apr 29;362(6423):841-4 16013991 - Expert Opin Pharmacother. 2005 Jul;6(8):1421-3 17210852 - Arch Ophthalmol. 2007 Jan;125(1):55-62 9383468 - Chem Biol. 1995 Oct;2(10):633-8 9168972 - Biochem Biophys Res Commun. 1997 May 8;234(1):117-20 10548435 - In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):533-42 11919187 - J Biol Chem. 2002 Jun 7;277(23):20756-62 16387003 - Am J Ophthalmol. 2006 Jan;141(1):200-1 17290195 - Retina. 2007 Feb;27(2):150-8 17317399 - Am J Ophthalmol. 2007 Mar;143(3):512-3 15036570 - Brain Res Bull. 2004 Feb 15;62(6):549-53 3531959 - Ophthalmology. 1986 Jul;93(7):989-97 12203970 - Chembiochem. 2002 Aug 2;3(8):717-25 9383475 - Chem Biol. 1995 Oct;2(10):683-95 7687750 - Nature. 1993 Aug 5;364(6437):550-3 15251751 - Endocr Pract. 1998 Mar-Apr;4(2):86-8 16518379 - Nat Rev Drug Discov. 2006 Feb;5(2):123-32 9238164 - Bull Cancer. 1997 Apr;84(4):397-405 14523912 - Chembiochem. 2003 Oct 6;4(10):963-71 17297464 - Oncogene. 2007 Jul 5;26(31):4531-40 7971962 - Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10779-85 15211173 - Int Ophthalmol Clin. 2004 Summer;44(3):11-22 11927845 - Retina. 2002 Apr;22(2):143-52 17481842 - J Pharm Biomed Anal. 2007 Jul 27;44(3):701-10 1857967 - Science. 1991 Jul 19;253(5017):314-7 3756910 - Cancer Res. 1986 Nov;46(11):5629-32 8127651 - Nucleic Acids Res. 1994 Jan 11;22(1):20-4 10198434 - Nucleic Acids Res. 1999 May 1;27(9):2006-14 12506087 - Invest Ophthalmol Vis Sci. 2003 Jan;44(1):290-9 16845209 - Pharmacol Rep. 2006 May-Jun;58(3):353-63 7520755 - Biochemistry. 1994 Aug 30;33(34):10450-6 16637665 - J Am Chem Soc. 2006 May 3;128(17):5966-73 16678158 - Exp Eye Res. 2006 Sep;83(3):615-9 17184527 - Health Qual Life Outcomes. 2006 Dec 21;4:97 10471678 - Clin Chem. 1999 Sep;45(9):1628-50 16255691 - Clin Exp Optom. 2005 Sep;88(5):322-34 15661835 - J Appl Physiol (1985). 2005 Jun;98(6):2137-46 16794266 - Stem Cells. 2006 Oct;24(10):2220-31 17017882 - Comb Chem High Throughput Screen. 2006 Sep;9(8):619-32 12750101 - Ophthalmology. 2003 May;110(5):979-86 7541132 - Nucleic Acids Res. 1995 Jun 11;23(11):2019-24 12124351 - Cancer Res. 2002 Jul 15;62(14):4123-31 1697402 - Nature. 1990 Aug 30;346(6287):818-22 9736491 - Bioconjug Chem. 1998 Sep-Oct;9(5):573-82 15013873 - Am J Ophthalmol. 2004 Mar;137(3):486-95 16154196 - Ophthalmology. 2005 Oct;112(10):1747-57 15648255 - Pharm Res. 2004 Dec;21(12):2234-46 16483659 - Ophthalmology. 2006 Apr;113(4):633.e1-4 17304258 - Eye (Lond). 2007 Dec;21(12):1511-5 9826651 - Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14051-6 17210851 - Arch Ophthalmol. 2007 Jan;125(1):49-54 11705996 - J Biol Chem. 2002 Jan 18;277(3):2104-11 16594622 - Handb Exp Pharmacol. 2006;(173):305-26 |
| References_xml | |
| SSID | ssj0062087 |
| Score | 1.9879519 |
| Snippet | Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors... |
| SourceID | pubmedcentral proquest pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 393 |
| SubjectTerms | Ligands Macular degeneration Review Vascular endothelial growth factor |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDI54SIgL4s14KQeuEW3Txs0JIbSBkOAEaLfKSRNtEmvL1v1_ki4bgwO9uqoqx3G-2J9tQm4s5ErEImGClyVLjU0Ygo5YZHOrAVCh8qGBl1fx9J4-D7NhCLjNAq1y6RM7R13W2sfIb5PuASmTu-aL-alRPrsaRmhsku04iYSndMFwdeESSZSH4SrAsjBK_i-K_EuGXDtdBvtkL8BCer9YxwOyYapDsvMSEt9H5GON3ENrSx1so04nY_bRfxxQbFqcmClta4p0raKKoi-cog6X0mUFJK2bUTvCz0kXTj8m74P-28MTCyMRWOPO8ZZpqzJpeF5qLVVuHdiQWcodBEEpEsQY3X0nKrUCm_E0L7PISOSx5hArnqHzbidkq6orc0YoBwlcqBhjY9IUcxmn2n0B0EonsNgjl0tlFcGuZ8XPKvQIXYmdRfo0A1amns8K4DwDcMiwR04Xqi2aReeMwm134SCe6BH4pfTVC77Z9W9JNR51Ta8T8M3f-fn_f3VBdrvga8c3uSRb7XRurhxqaNV1ZxrfuFfGYw priority: 102 providerName: ProQuest |
| Title | Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/19668516 https://www.proquest.com/docview/2222227992 https://search.proquest.com/docview/733577519 https://pubmed.ncbi.nlm.nih.gov/PMC2704523 |
| Volume | 1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-aDsZexrqvph9BD3tVY1uWZD22JVkYpJSxluzJnGSJBBrbtO7_v7Njl3TsaX4wmLMkOB2nn06_OwF8CzqzKlYJV6IoeOpDwlG7iEchC05rtGjb0MDyRi3u0h8ruToAOeTCdKR9ZzcX5cP2otysO25lvXXTgSc2vV1eJ7otBC6mIxiRgQ5b9J37VUmU9TeqaC7JDXRlQZUiZKH-hSL_JkPurS7zD_C-h4Xscjf8ERz48iO8XfYH35_gfo_cw6rACLYx0smG38--zxnWDW79I2sqhmwvo4phmzjFCJeyIQOSVfW6WePDtgunf4a7-ezX9YL3VyLwmtbxhrtgpfEiK5wzNgsENoxMBUEQNCpBjJH2O1HhrA5SpFkhI29QxE7o2AqJ5N2-wGFZlf4YmNBGC2VjjL1PU8xMnDrqQWMwJAg4hrNBWXlv10950j3amGQM7EVMFtkeM2Dpq-enXAshtSZkOIavO9Xm9a5yRj5MxBj0K6W__NAWu34tIRvoil73c37y3y1P4V0Xl-2oKGdw2Dw--3MCFI2dwCj6vaC3XukJvLma3dz-pK9lmk060_oDGcrTow |
| link.rule.ids | 230,315,730,783,787,888,2228,12068,21400,31731,31732,33756,33757,43322,43817,53804,53806,74073,74630 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED8xkGAvaHxtZR3zA68WSZzY8RNiqF3HaIUQIN6is2OrSCMJNP3_sVMXCg_L60VRdD6ff76P3wEcW5ErHvOEclaWNDU2oSh0RCObWy0EKlQ-NDCe8NFtenGf3YeA2yyUVS59Yueoy1r7GPlJ0j1CyuS0eaJ-apTProYRGp9gw1NVucvXxq_B5Op66Yt5EuVhvIqgWRgm_xFHfiyHXDlfhl9gOwBDcrZYyR1YM9UubI5D6nsP7lbKe0htiQNuxGnlgd4Nfg8JNi0-mmfS1gTJSk8VQd86RRwyJcseSFI303aK_x67gPo-3A4HN-cjGoYi0Mad5C3VVmXSsLzUWqrcOrghs5Q5EIKSJ4gxuhtPVGolbMbSvMwiI5HFmolYsQydfzuA9aquzDcgTEjBuIoxNiZNMZdxqt0XBFrpBBZ70F8qqwiWPSve1qEH5FXsbNInGrAy9XxWCMYyIRw27MHXhWqLZsGdUbgNzx3I4z0Q75T--oKnu34vqR6mHe11Ijz9Ozv8_1_9hK3RzfiyuPwz-fsdPneh2K76pA_r7fPc_HAYolVHwVBeAJdByrk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB61i4R6qaCFsjxaH3q1SOLEE58Qj13ogxVCgLhFY8fWIpUksOH_42S9sHBorhNF1ngy_jzzzQzAT4e5lrFMuBRlyVPrEk5oIh653BlE0qS70MD5RJ5dp79vs9vAf5oFWuXCJ_aOuqxNFyPfT_oHlUr2XaBFXJyMD5oH3k2Q6jKtYZzGR1jBVIpoACtHo8nF5cIvyyTKw6gV5FkYLP8eU76nRi6dNeM1-BxAIjuc7-o6fLDVF1g9D2nwr3CzRPVhtWMexDGvoTt-MzodM2paurePrK0ZsaX6KkZdGRXzKJUt6iFZ3UzbKf2774PrG3A9Hl0dn_EwIIE3_lRvuXE6U1bkpTFK585DD5WlwgMSUjIhisnffqLSaHSZSPMyi6wiERuBsRYZeV-3CYOqruwWMIEKhdQxxdamKeUqTo3_ApJTXuBoCLsLZRXBymfF654Mgb2IvX12SQeqbP00K1CIDNHjxCF8m6u2aOZ9NAr_80sP-OQQ8I3SX17oWl-_lVR3074FdoJdK3ix_f9V_YBVbyPF31-TPzvwqY_K9kSUXRi0j092z8OJVn8PdvIMn7nO5w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+the+anti-VEGF+aptamer+to+a+therapeutic+agent+for+clinical+ophthalmology&rft.jtitle=Clinical+ophthalmology+%28Auckland%2C+N.Z.%29&rft.au=Trujillo%2C+Cleber+A&rft.au=Nery%2C+Arthur+A&rft.au=Jana%C3%AD%C2%ADna+M+Alves&rft.au=Martins%2C+Antonio+H&rft.date=2007-12-01&rft.pub=Taylor+%26+Francis+Ltd&rft.issn=1177-5467&rft.eissn=1177-5483&rft.volume=1&rft.issue=4&rft.spage=393&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1177-5467&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1177-5467&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1177-5467&client=summon |